purple-biotech.com (PPBT) - מזומן למניה

Purple Biotech is strengthening its image in onco-immunology by developing effective combination therapies. The quarterly cash per share trend on GURU.Markets illustrates the market reaction, while the 3.17 metric confirms the current level. The firm's stability is based on venture R&D funding, and the continuity of research is ensured by the diversification of chemical formula supply centers.
פילוחים אנליטיים של חברת Purple Biotech

Cash per share determines the portion of liquid assets attributable to a single security. This metric measures the internal capital cushion available to cover operating expenses without incurring debt. By analyzing the cash per share trend, an investor assesses a company's autonomy. For Purple Biotech (PPBT), this resource is critical when funding costly clinical trials for oncology drugs. Sufficient cash minimizes bankruptcy risks until the therapy reaches commercialization.